The new program, a combined $45-million-dollar, multi-year commitment, will train early career scientists who have historically been underrepresented in biotech to spur the development of novel therapeutics for childhood diseases.
The new program, a combined $45-million-dollar, multi-year commitment, will train early career scientists who have historically been underrepresented in biotech to spur the development of novel therapeutics for childhood diseases.